Gastroenterology — MCQs

Gastroenterology Indian Medical PG Practice Questions and MCQs

Question 721: Which of the following is a risk factor for cholangiocarcinoma?

A. Pancreatitis
B. Caroli disease (Correct Answer)
C. Pyelonephritis
D. Ulcerative colitis

Explanation: **Explanation:** Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial lining of the biliary tree [2]. The primary underlying mechanism for its development is **chronic biliary inflammation and stasis**, which leads to DNA damage and malignant transformation of cholangiocytes. **Why Caroli Disease is Correct:** **Caroli disease** is a rare congenital disorder characterized by multifocal, segmental dilatation of the large intrahepatic bile ducts [1]. It is a potent risk factor for cholangiocarcinoma (occurring in approximately 7-15% of cases) because the cystic dilatations lead to **bile stasis, recurrent cholangitis, and hepatolithiasis**, all of which induce chronic mucosal irritation and dysplasia. **Analysis of Incorrect Options:** * **A. Pancreatitis:** While chronic pancreatitis is a risk factor for pancreatic adenocarcinoma, it is not directly linked to the development of cholangiocarcinoma. * **C. Pyelonephritis:** This is an infection of the renal pelvis and kidney parenchyma; it has no anatomical or physiological association with the biliary tree. * **D. Ulcerative Colitis:** This is a "distractor" because **Primary Sclerosing Cholangitis (PSC)**—which is strongly associated with Ulcerative Colitis—is the most common risk factor for CCA in the West [1]. However, UC itself, in the absence of PSC, does not significantly increase the risk of biliary tract cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Most common risk factor worldwide:** Liver fluke infections (*Opisthorchis viverrini* and *Clonorchis sinensis*). * **Most common risk factor in the West:** Primary Sclerosing Cholangitis (PSC). * **Other high-yield risk factors:** Choledochal cysts (Todani classification), hepatolithiasis, Thorotrast exposure, and Hepatitis B/C. * **Tumor Marker:** **CA 19-9** is frequently elevated in cholangiocarcinoma. * **Klatskin Tumor:** A specific type of hilar cholangiocarcinoma occurring at the confluence of the right and left hepatic ducts [2].

Question 722: Which of the following is NOT true about acute pancreatitis?

A. Gallstones and alcohol are common etiologies.
B. Serum amylase levels remain elevated more than 72 hours after the onset of the attack. (Correct Answer)
C. It can cause a secondary pleural effusion.
D. It can present with shock.

Explanation: **Explanation:** Acute pancreatitis is an inflammatory condition of the pancreas characterized by abdominal pain and elevated pancreatic enzymes [1]. **1. Why Option B is the Correct Answer (False Statement):** Serum amylase typically rises within 2–12 hours of the onset of symptoms and has a **short half-life**. It usually returns to normal levels within **3 to 5 days (48–72 hours)**. Therefore, the statement that it *remains* elevated beyond 72 hours is generally incorrect. In contrast, **Serum Lipase** remains elevated for a longer duration (7–14 days), making it a more sensitive marker for delayed presentations. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** Gallstones (obstructive) and Alcohol (toxic-metabolic) are the two most common causes of acute pancreatitis worldwide, accounting for nearly 80% of cases. * **Option C:** Pancreatitis can cause a secondary pleural effusion (typically **left-sided**) due to diaphragmatic inflammation or a pancreatic-pleural fistula. The fluid is characterized by high amylase levels. * **Option D:** Severe acute pancreatitis can lead to systemic inflammatory response syndrome (SIRS), massive third-space fluid loss, and hemorrhage, resulting in **hypovolemic or septic shock** [1]. **Clinical Pearls for NEET-PG:** * **Diagnosis:** Requires 2 of 3 criteria: (1) Typical epigastric pain, (2) Amylase/Lipase >3x upper limit, (3) Characteristic imaging findings. * **Lipase vs. Amylase:** Lipase is more specific and remains elevated longer than amylase. * **Prognostic Scoring:** Ranson’s Criteria, APACHE II, and the **BISAP score** are high-yield for predicting severity [1]. * **Imaging:** Contrast-Enhanced CT (CECT) is the gold standard but is best performed **72 hours after onset** to accurately assess necrosis [2].

Question 723: Treatment of H. pylori is required in all of the following conditions EXCEPT?

A. Gastroesophageal reflux disease (Correct Answer)
B. Gastric ulcers
C. Duodenal ulcers
D. Gastric lymphoma

Explanation: **Explanation:** The primary goal of *H. pylori* eradication is to prevent complications such as peptic ulcer disease (PUD) [1] and gastric malignancy [3]. **1. Why Gastroesophageal Reflux Disease (GERD) is the correct answer:** There is no proven causal link between *H. pylori* infection and the development of GERD [2]. In fact, some studies suggest that *H. pylori* infection (especially strains causing corpus gastritis) may have a protective effect against GERD and its complications (like Barrett's esophagus) by reducing gastric acid secretion. Eradication of the bacteria does not improve GERD symptoms and, in some cases, may paradoxically worsen them [2]. Therefore, GERD is not a standard indication for testing or treating *H. pylori*. **2. Why the other options are incorrect:** * **Gastric and Duodenal Ulcers:** *H. pylori* is the most common cause of peptic ulcers. Eradication is mandatory as it promotes ulcer healing and significantly reduces the rate of recurrence and complications like bleeding [1]. * **Gastric Lymphoma:** Specifically, **MALToma** (Mucosa-Associated Lymphoid Tissue lymphoma) is strongly associated with *H. pylori* [3]. In early-stage (low-grade) MALToma, eradication of the bacteria alone can lead to complete regression of the tumor in up to 70-80% of cases [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Definitive Indications for Eradication:** PUD (active or history of), MALToma, early gastric cancer (post-resection), and first-degree relatives of gastric cancer patients. * **Diagnostic Gold Standard:** Endoscopic biopsy followed by **Rapid Urease Test (RUT)** or Histopathology [1]. * **Non-invasive Test of Choice:** **Urea Breath Test (UBT)** is the best for confirming eradication (done 4 weeks after treatment) [1]. * **First-line Treatment:** Standard Triple Therapy (PPI + Clarithromycin + Amoxicillin/Metronidazole) for 14 days.

Question 724: Which of the following is NOT true about ulcerative colitis?

A. Rectum is typically involved
B. Pseudopolyps can be present
C. Pancolitis may occur
D. Noncaseating granulomas are characteristic (Correct Answer)

Explanation: The correct answer is **D**. Ulcerative Colitis (UC) is characterized by continuous mucosal inflammation limited to the colon [1]. **Noncaseating granulomas** are the hallmark histological feature of **Crohn’s Disease**, not Ulcerative Colitis. In UC, the inflammation is superficial (mucosal and submucosal), whereas Crohn’s is transmural [1]. **Analysis of Options:** * **A. Rectum is typically involved:** This is a key feature of UC. The disease almost always starts in the rectum (**proctitis**) and spreads proximally in a continuous fashion [1]. * **B. Pseudopolyps can be present:** These are "islands" of regenerating or normal mucosa surrounded by areas of extensive ulceration [1]. They are a common finding in chronic UC. * **C. Pancolitis may occur:** While UC starts in the rectum, it can progress to involve the entire colon up to the cecum, a condition known as pancolitis [1]. **NEET-PG High-Yield Pearls:** 1. **Histology of UC:** Look for **crypt abscesses** (neutrophils in crypt lumens) and crypt distortion [1]. Granulomas are absent. 2. **Smoking Paradox:** Smoking is **protective** in UC but a risk factor for Crohn’s Disease. 3. **Lead Pipe Appearance:** Chronic UC leads to loss of haustrations, seen on barium enema as a "lead pipe" colon. 4. **Complications:** UC has a higher risk of **Toxic Megacolon** and **Primary Sclerosing Cholangitis (PSC)** compared to Crohn’s. 5. **Serology:** UC is typically associated with **p-ANCA**, while Crohn’s is associated with **ASCA**.

Question 725: Which of the following conditions is associated with an increased risk of developing adenocarcinoma of the esophagus?

A. Barrett's esophagus (Correct Answer)
B. Long-standing achalasia
C. Corrosive stricture
D. Alcohol abuse

Explanation: The development of esophageal cancer is broadly divided into two histological types: **Adenocarcinoma** and **Squamous Cell Carcinoma (SCC)**. Understanding their distinct risk factors is crucial for NEET-PG. **1. Why Barrett's Esophagus is correct:** Barrett’s esophagus is the most significant precursor to **Adenocarcinoma** [1]. It occurs due to chronic Gastroesophageal Reflux Disease (GERD), where the normal stratified squamous epithelium of the lower esophagus undergoes metaplasia into simple columnar epithelium (with goblet cells). This metaplasia-dysplasia-carcinoma sequence specifically leads to adenocarcinoma, typically in the distal third of the esophagus [1]. **2. Why other options are incorrect:** * **Long-standing Achalasia:** While it increases the risk of esophageal cancer (due to food stasis and chronic inflammation), it is primarily associated with **Squamous Cell Carcinoma**, not adenocarcinoma. * **Corrosive Stricture:** Ingestion of lye or other corrosives causes chronic scarring and inflammation, which significantly increases the risk of **Squamous Cell Carcinoma** (often occurring decades after the initial insult). * **Alcohol Abuse:** Alcohol is a major risk factor for **Squamous Cell Carcinoma**. Interestingly, alcohol has not been strongly linked to adenocarcinoma; however, **obesity** and **smoking** are major risk factors for the adenocarcinoma subtype [1]. **Clinical Pearls for NEET-PG:** * **Location:** Adenocarcinoma is usually found in the **lower third**; SCC is more common in the **upper and middle thirds**. * **Most common type:** Globally, SCC is more common; however, in Western countries, the incidence of Adenocarcinoma is rising rapidly due to obesity and GERD [1]. * **Protective Factor:** *H. pylori* infection is paradoxically associated with a *decreased* risk of esophageal adenocarcinoma (likely due to reduced gastric acid production).

Question 726: The Child-Turcotte-Pugh (CTP) score is used for the assessment of severity in which of the following conditions?

A. Cirrhosis (Correct Answer)
B. Hepatocellular carcinoma
C. Biliary atresia
D. None of the above

Explanation: **Explanation:** The **Child-Turcotte-Pugh (CTP) score** is a validated clinical tool used primarily to assess the prognosis and severity of **Cirrhosis** (chronic liver disease) [1]. It predicts the 1-year and 2-year survival rates and helps determine the necessity of liver transplantation. The score is calculated using five parameters (Mnemonic: **ABCDE**): 1. **A**lbumin 2. **B**ilirubin 3. **C**oagulation (INR/Prothrombin Time) 4. **D**istension (Ascites) 5. **E**ncephalopathy **Analysis of Options:** * **A. Cirrhosis (Correct):** CTP categorizes patients into Classes A (5–6 points), B (7–9 points), and C (10–15 points), reflecting increasing severity and mortality risk [1]. * **B. Hepatocellular Carcinoma (HCC):** While CTP is used to assess the underlying liver function in HCC patients, the specific staging system for HCC is the **BCLC (Barcelona Clinic Liver Cancer)** staging. * **C. Biliary Atresia:** The severity of liver disease in the pediatric population (including biliary atresia) is assessed using the **PELD (Pediatric End-stage Liver Disease)** score, rather than CTP [1]. **High-Yield Clinical Pearls for NEET-PG:** * **MELD Score:** Unlike CTP, the MELD (Model for End-Stage Liver Disease) score is purely objective (Bilirubin, Creatinine, INR) and is the primary tool for **organ allocation** in liver transplants [1]. * **CTP Limitations:** It includes subjective parameters like the grading of ascites and encephalopathy, which can be influenced by medical intervention (e.g., diuretics or lactulose) [1]. * **Class C** indicates a 1-year survival rate of approximately 45%, signifying decompensated cirrhosis.

Question 727: Which of the following is NOT useful for the management of severe Clostridium difficile infection?

A. Intravenous metronidazole
B. Neomycin enema (Correct Answer)
C. Fecal transplant
D. Tigecycline

Explanation: The management of **severe or fulminant *Clostridioides difficile* infection (CDI)** requires systemic or luminal antibiotics that are effective against anaerobic Gram-positive bacilli. **Why Neomycin is NOT useful:** Neomycin is an **aminoglycoside**. Aminoglycosides are primarily effective against aerobic Gram-negative bacteria and have **no activity against anaerobes** like *C. difficile* [1]. Furthermore, neomycin is poorly absorbed from the gut; while this is useful for hepatic encephalopathy or bowel prep, it lacks the spectrum required to treat CDI [1]. In fact, use of broad-spectrum antibiotics like aminoglycosides or cephalosporins can predispose a patient to CDI by disrupting normal gut flora [2]. **Analysis of other options:** * **IV Metronidazole:** In fulminant CDI (characterized by hypotension, shock, ileus, or megacolon), IDSA guidelines recommend combining **oral Vancomycin with IV Metronidazole**. IV Metronidazole is used because it reaches the inflamed colon via biliary excretion and capillary diffusion, especially when ileus prevents oral drugs from reaching the site [1]. * **Fecal Microbiota Transplant (FMT):** This is highly effective for **recurrent CDI** and is increasingly considered for severe cases that are refractory to standard antibiotic therapy to restore healthy gut microbiome. * **Tigecycline:** This is a glycylcycline with potent activity against *C. difficile*. It is often used as a **rescue therapy** in severe, refractory cases due to its high fecal concentrations and ability to inhibit toxin production [1]. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice (DOC):** Oral **Fidaxomicin** or oral **Vancomycin** are now preferred over Metronidazole for initial episodes. 2. **Fulminant CDI:** Defined by hypotension, shock, ileus, or megacolon. Treatment: High-dose oral Vancomycin + IV Metronidazole + Vancomycin enemas. 3. **Diagnosis:** The most sensitive test is NAAT (PCR for toxin gene); the most specific is the Cell Cytotoxicity Assay. 4. **Avoid:** Anti-motility agents (like Loperamide) as they increase the risk of toxic megacolon.

Question 728: What is the treatment of choice for Zollinger Ellison syndrome (ZES)?

A. Proton pump inhibitors (PPIs) (Correct Answer)
B. Somatostatin analogues
C. Streptozocin
D. Sucralfate

Explanation: **Explanation:** **Zollinger-Ellison Syndrome (ZES)** is characterized by a gastrin-secreting tumor (gastrinoma), leading to massive gastric acid hypersecretion and severe peptic ulcer disease. 1. **Why PPIs are the Treatment of Choice:** The primary goal in managing ZES is the control of gastric acid hypersecretion to prevent complications like perforation or strictures. **Proton Pump Inhibitors (PPIs)**, such as Omeprazole or Pantoprazole, are the drugs of choice because they irreversibly inhibit the $H^+/K^+$ ATPase pump, the final common pathway of acid secretion. They are highly effective, have a long duration of action, and can be titrated to high doses to achieve complete symptom control. 2. **Analysis of Incorrect Options:** * **Somatostatin analogues (e.g., Octreotide):** While they can inhibit gastrin release, they are less effective than PPIs for long-term acid control and are generally reserved for refractory cases or tumor localization. * **Streptozocin:** This is a chemotherapeutic agent used for metastatic gastrinomas (palliative care), not for the primary management of acid hypersecretion. * **Sucralfate:** This is a mucosal protective agent. It does not address the underlying pathophysiology (hypergastrinemia) and is insufficient to manage the massive acid output in ZES. **Clinical Pearls for NEET-PG:** * **Location:** Most gastrinomas are found in the **"Gastrinoma Triangle"** (confluence of cystic/common bile duct, junction of 2nd/3rd part of duodenum, and neck/body of pancreas). * **Association:** Approximately 25% of ZES cases are associated with **Multiple Endocrine Neoplasia type 1 (MEN1)**. * **Diagnosis:** The best initial screening test is **Fasting Serum Gastrin (>1000 pg/mL)**. The most sensitive provocative test is the **Secretin Stimulation Test** (paradoxical rise in gastrin). * **Definitive Treatment:** Surgical resection is the only curative treatment for sporadic, non-metastatic gastrinomas.

Question 729: What is true about Crigler-Najjar syndrome type II?

A. Associated with diglucuronide deficiency
B. Inherited as a recessive trait (Correct Answer)
C. Kernicterus is commonly seen
D. Phenobarbital is not useful in management

Explanation: Crigler-Najjar Syndrome (CNS) is a rare genetic disorder characterized by non-hemolytic unconjugated hyperbilirubinemia due to a deficiency of the enzyme **UDP-glucuronosyltransferase (UGT1A1)** [1]. **1. Why Option B is Correct:** Crigler-Najjar Type II (also known as **Arias Syndrome**) is inherited as an **autosomal recessive** trait (though some rare cases show dominant inheritance with variable penetrance). It involves a partial deficiency of UGT1A1, with enzyme activity typically <10% of normal [1]. **2. Analysis of Incorrect Options:** * **Option A:** CNS Type II is associated with a deficiency of **monoglucuronides** and **diglucuronides** (conjugated bilirubin), leading to a rise in unconjugated bilirubin [2]. * **Option C:** Kernicterus (bilirubin encephalopathy) is **rare** in Type II because bilirubin levels usually stay between 6–20 mg/dL. In contrast, Kernicterus is common and often fatal in **CNS Type I**, where bilirubin levels exceed 20–50 mg/dL [1]. * **Option D:** Phenobarbital is the **mainstay of treatment** for Type II. It acts as an enzyme inducer, stimulating the residual UGT1A1 activity and reducing serum bilirubin by 25% or more [2]. In Type I, Phenobarbital has no effect because enzyme activity is completely absent [1]. **High-Yield Clinical Pearls for NEET-PG:** * **CNS Type I:** Autosomal Recessive; 0% enzyme activity; No response to Phenobarbital; Treatment: Phototherapy, Plasmapheresis, Liver Transplant [1]. * **CNS Type II:** Autosomal Recessive; <10% enzyme activity; **Responds to Phenobarbital** [1]. * **Gilbert Syndrome:** Most common hereditary hyperbilirubinemia; ~30% enzyme activity; triggered by stress/fasting [1].

Question 730: Secretory diarrhea is not seen in which of the following conditions?

A. Magnesium injection
B. Celiac disease (Correct Answer)
C. Cholera
D. Ulcerative colitis

Explanation: The core concept in this question is differentiating between the mechanisms of diarrhea. **Secretory diarrhea** occurs when there is active secretion of electrolytes (primarily chloride and bicarbonate) and water into the intestinal lumen, or inhibition of their absorption, independent of food intake. **Why Celiac Disease is the correct answer:** Celiac disease primarily causes **Malabsorptive/Osmotic diarrhea**. The underlying pathology involves immune-mediated destruction of the small intestinal villi (villous atrophy), leading to a reduced surface area for nutrient absorption [1]. The pathophysiology involves gluten-induced Th1 immune responses, lymphocytic infiltration of the lamina propria, crypt hyperplasia, and villous atrophy [1]. Unabsorbed nutrients remain in the lumen, creating an osmotic gradient that pulls water into the gut. Unlike secretory diarrhea, osmotic diarrhea typically **improves or resolves with fasting.** **Analysis of Incorrect Options:** * **Magnesium Ingestion:** Magnesium salts (e.g., magnesium hydroxide) act as osmotic laxatives, but in high doses or specific formulations, they can also stimulate the secretion of cholecystokinin and other secretagogues, contributing to a secretory component. * **Cholera:** This is the classic prototype of secretory diarrhea. The *Vibrio cholerae* toxin increases intracellular cAMP, leading to massive, active secretion of chloride ions via the CFTR channels, followed by water. * **Ulcerative Colitis (UC):** While primarily inflammatory, UC causes diarrhea through multiple mechanisms [2]. The inflammation leads to the release of secretagogues (prostaglandins, cytokines) and damage to the epithelial cells' ability to absorb sodium, resulting in a significant secretory component alongside blood and mucus. **NEET-PG High-Yield Pearls:** * **Secretory Diarrhea:** High stool volume (>1L/day), **Normal Osmotic Gap** (<50 mOsm/kg), and persists during fasting. * **Osmotic Diarrhea:** Smaller volume, **High Osmotic Gap** (>125 mOsm/kg), and stops with fasting. * **Formula for Stool Osmotic Gap:** $290 - 2 \times (\text{Stool Na}^+ + \text{Stool K}^+)$. * **Common Secretory Causes:** VIPoma (WDHA syndrome), Carcinoid syndrome, Cholera, and Bile acid malabsorption.

Practice by Chapter

Esophageal Disorders

Practice Questions

Peptic Ulcer Disease

Practice Questions

Inflammatory Bowel Disease

Practice Questions

Irritable Bowel Syndrome

Practice Questions

Malabsorption Syndromes

Practice Questions

Pancreatitis (Acute and Chronic)

Practice Questions

Gastrointestinal Bleeding

Practice Questions

Liver Diseases and Cirrhosis

Practice Questions

Viral Hepatitis

Practice Questions

Biliary Tract Disorders

Practice Questions

Gastrointestinal Motility Disorders

Practice Questions

Gastrointestinal Malignancies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free